How long does iron take to correct deficiency, and when to retest?

Last reviewed 13 May 2026

This entry is part of the Nutri Tailor Health Reference Library — cited research on supplements, nutrients and adjacent areas of health.

Summary

Iron repletion runs in two phases at different speeds. Haemoglobin recovers in weeks; ferritin in months. Per BSG 2021: oral iron raises haemoglobin within 1-2 weeks and normalises Hb within 6-8 weeks. Continue 3 months past Hb normalisation to replenish stores. Endpoint is clinical (symptom resolution, restored stores), not a numerical ferritin target. Standard retest schedule: FBC at 2-4 weeks, FBC plus ferritin at 8-12 weeks, final ferritin at 6 months.

How it works

Moretti 2015 (Blood 126(17):1981-1989, PMID 26289639) demonstrated that consecutive-day dosing of 60 mg elemental iron triggered hepcidin elevations reducing absorption from the next dose by 35-45%. Stoffel 2017 (Lancet Haematol 4(11):e524-e533, PMID 29032957), Stoffel 2020 (Haematologica 105(5):1232-1239) confirmed the practical implication: alternate-day dosing achieves higher cumulative fractional absorption and comparable haemoglobin response with fewer GI side effects than consecutive-day dosing.

Effective dose

Form choice does not materially change the repletion timeline. BSG 2021 considers ferrous sulphate, fumarate, and gluconate equivalent first-line options for repletion. Iron bisglycinate has tolerability advantages but no proven superiority on absorption rate or repletion speed. Switching between traditional iron salts is not evidence-supported.

Timing

Ferritin trails haemoglobin substantially. After Hb normalises, ferritin continues to rise over a further 3-6 months on continued repletion. BSG 2021 recommends continuing oral iron for 3 months past Hb normalisation rather than stopping at the first normal Hb. Standard retest schedule: FBC at 2-4 weeks; FBC plus ferritin at 8-12 weeks; final ferritin at around 6 months. For IDWA: no Hb endpoint, so retest ferritin and FBC at 8-12 weeks.

Safety profile

Documented causes of slower-than-expected response: ongoing blood loss (heavy menstrual or occult gastrointestinal); malabsorption (coeliac disease, IBD, atrophic gastritis, H. pylori, post-bariatric); inflammation suppressing absorption and elevating ferritin (Ganz 2019 NEJM 381(12):1148-1157, PMID 31532961); consecutive-day dosing hitting hepcidin rebound (Moretti 2015); co-administration with calcium, polyphenols, or antacids; thyroid medication interaction requiring spacing; inadequate dose or non-adherence driven by GI side effects (Tolkien 2015 PLoS One 10(2):e0117383, PMID 25700159).

Special populations

In IDWA, retest ferritin and FBC at 8-12 weeks; if response is inadequate, reassess underlying cause rather than escalating dose blindly. Repletion duration in IDWA is more individualised than in IDA because no Hb endpoint forces the question; typically 3-6 months with ferritin retest before stopping. Pregnancy: iron requirements rise substantially; routine antenatal screening covers iron, B12, and folate. Inflammatory contexts: paired ferritin and CRP avoids misreading falsely elevated ferritin as repletion.

Interactions

Concurrent intake of these inhibitors with iron can blunt absorption and slow repletion. Practical mitigation: take iron away from these (1-2 hours before or after coffee, tea, or calcium-containing foods; at least 4 hours from levothyroxine). Stoffel/Moretti programme findings on alternate-day dosing apply regardless of these timing arrangements.

Interaction	Issue	Guidance	Citation
Iron and calcium	Calcium reduces non-haem iron absorption	Separate iron supplements from calcium-containing meals by around 2 hours	NIH ODS — Iron Fact Sheet for Health Professionals
Iron and tea polyphenols	Polyphenols in tea reduce non-haem iron absorption	Separate iron supplements from tea by 1-2 hours	NIH ODS — Iron Fact Sheet for Health Professionals
Iron and coffee polyphenols	Polyphenols in coffee reduce non-haem iron absorption	Separate iron supplements from coffee by 1-2 hours	NIH ODS — Iron Fact Sheet for Health Professionals

Guideline positions

Moretti 2015 (Blood 126(17):1981-1989, PMID 26289639), Stoffel 2017 (Lancet Haematol 4(11):e524-e533, PMID 29032957), Stoffel 2020 (Haematologica 105(5):1232-1239) underpin the alternate-day dosing approach. Tolkien 2015 (PLoS One 10(2):e0117383, PMID 25700159) quantifies GI tolerability of ferrous sulphate. Ganz 2019 (NEJM 381(12):1148-1157, PMID 31532961) covers anaemia of inflammation.

Practical framework

After 8-12 weeks of adequate adherence without expected response, BSG 2021 supports investigating underlying cause before concluding non-response: occult GI bleeding workup, coeliac serology, H. pylori testing, inflammatory markers, and review of co-administration patterns. Where investigation is complete and oral iron has genuinely failed or is not tolerated, parenteral iron (e.g. ferric carboxymaltose) is the BSG-supported next-line option. Krayenbuehl 2011 (Blood 118(12):3222-3227, PMID 21705493) anchors the IV iron measurement window at 6 weeks post-infusion. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: doubling the dose halves the timeline. The Tolkien 2015 meta-regression found no significant relationship between iron dose and GI side-effect rate. Higher single doses do not proportionally increase absorption because hepcidin elevation after each dose dampens subsequent uptake. The Moretti 2015 / Stoffel 2017 / Stoffel 2020 findings on alternate-day dosing are the practical answer to absorption efficiency, not dose escalation. Form switching between traditional iron salts is not evidence-supported.

Who this matters for

This entry is relevant for the following groups, conditions, and medication contexts:

Pregnancy
Breastfeeding
Adults over 65
Post-menopause
Inflammatory bowel disease
People taking levothyroxine
People taking proton pump inhibitors
Vegetarian diet

Recent updates

29 April 2026 — v3.1 -> v4 retrofit. (1) bottom_line: 3432 chars (multi-paragraph) to 71 words. (2) structured_sections from 9 keys to 10 canonical (mechanism, effective_dose, timing, safety_profile, special_populations, interactions, guideline_anchors, practical_framework, common_misconceptions, cross_references). idwa_vs_ida_differences folded into special_populations. inflammation_complication folded into safety_profile + special_populations. retest_schedule_uk_pathway became core of timing + practical_framework. treatment_duration_per_bsg renamed and content folded into timing + guideline_anchors (forbidden word in key). factors_that_slow_correction folded into safety_profile body. haemoglobin_recovery_timeline became canonical timing capsule. when_oral_iron_appears_to_fail folded into practical_framework body. ferritin_replenishment_timeline folded into timing body. alternate_day_dosing_consideration folded into mechanism body + effective_dose. (3) Multiple "treatment" replacements: "Treatment endpoint" became "Endpoint of repletion"; "Treatment duration" became "Repletion duration"; "treating iron deficiency anaemia" became "repleting iron deficiency anaemia"; "treatment failure" became "non-response". (4) Drafted dash-free; ~10 spaced hyphens cleaned up via parens, sentence breaks, or rewording. (5) Disclaimer updated. (6) population_tags: 8. medication_interactions: 6 (levothyroxine, PPI, tetracycline, fluoroquinolone, levodopa, antacid). supplement_interactions: 3.
28 April 2026 — Voice audit follow-up. Pre-v3.1 entry. Surgical edits: removed Camaschella, Ganz NEJM review surnames; reframed Moretti 2015 Blood paper as "2015 Swiss study published in Blood"; Stoffel 2017 Lancet Haematology as "2017 Swiss study"; Li 2020 meta-analysis dropped "by Li and colleagues".
27 April 2026 — v3.1.1 marketing-layer build for iron family P3 entry 2 of 3. Major v2 corrections: (1) advisor voice ("Retest at 3 months", "Continue until ferritin reaches target", "Do not stop", "Choosing a poorly absorbed form") replaced throughout with publisher voice reporting BSG 2021 framework; (2) "above 70 mcg/L symptom resolution target" and "above 100 mcg/L pregnancy target" REMOVED - both numerical targets are not BSG-anchored; BSG 2021 explicitly sets no specific ferritin target and uses clinical endpoint (cross-ref 0106e300 for full threshold framing); (3) "ferrous sulphate vs iron bisglycinate as poorly absorbed" framing REMOVED - directly contradicts BSG 2021 which considers traditional iron salts equivalent and notes switching not evidence-supported (cross-ref 9ad74456); (4) "below 5 ferritin requiring 6-12 months" claim removed - no source identified in pool; reframed as BSG 3-months-past-Hb-normalisation with clinical endpoint; (5) IDWA monitoring schedule made explicit and differentiated from IDA (no Hb endpoint to follow) with cross-ref dfb9e29c; (6) inflammation-as-timeline-distortion section added with Ganz 2019 NEJM anchor and cross-refs d6f6c8dd, 6c3f3b83; (7) alternate-day dosing-as-timeline-equivalent framing added with full Moretti/Stoffel/Li chain. Differentiated from sister entries 057873ab (full repletion focus), f482ea01 (symptom-resolution focus), a65f0df5 (energy timeline), 51763509 (sleep timeline), d6f3c974 (4-week non-response interpretation), 2d87f6cf (loading protocol). 12 sources, all from row 71 verified pool - no fresh PubMed verification required. Cross-refs deployed: dfb9e29c, 0106e300, df016a3e, 9ad74456, d6f6c8dd, 6c3f3b83, 90e23a9d, 1035a4cd, ae372e9d, 7e45914b.

Sources

Snook J, Bhala N, Beales ILP, Cannings D, Kightley C, Logan RPH, Pritchard DM, Sidhu R, Surgenor S, Thomas W, Verma AM 2021. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. PMID: 34497146 · DOI: 10.1136/gutjnl-2021-325210
Camaschella C 2015. Iron-deficiency anemia. New England Journal of Medicine. PMID: 25946282 · DOI: 10.1056/nejmra1401038
Camaschella C 2019. Iron deficiency. Blood. PMID: 30401704 · DOI: 10.1182/blood-2018-05-815944
Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H, Melse-Boonstra A, Brittenham G, Swinkels DW, Zimmermann MB 2015. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. PMID: 26289639 · DOI: 10.1182/blood-2015-05-642223
Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, Moretti D, Zimmermann MB 2017. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematology. PMID: 29032957 · DOI: 10.1016/s2352-3026(17)30182-5
Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB 2020. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica. PMID: 31413088 · DOI: 10.3324/haematol.2019.220830
Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ 2015. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. PMID: 25700159 · DOI: 10.1371/journal.pone.0117383
Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, Bischoff T, de Vevey M, Studer JP, Herzig L, Chapuis C, Tissot J, Pécoud A, Favrat B 2003. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ. PMID: 12763985 · DOI: 10.1136/bmj.326.7399.1124
Vaucher P, Druais P-L, Waldvogel S, Favrat B 2012. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ. PMID: 22777991 · DOI: 10.1503/cmaj.110950
Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G 2011. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. PMID: 21705493 · DOI: 10.1182/blood-2011-04-346304
Ganz T 2019. Anemia of inflammation. New England Journal of Medicine. PMID: 31532961 · DOI: 10.1056/nejmra1804281

Back to Iron overview